JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - EUPRAXIA PHARMACEUTICALS INC
Financial Performance:
- Cash Position: The company maintains sufficient cash and short-term investments to fund operations until Q3 2028, covering the current trial, the initiation of Phase 3, and the execution of a Phase 2 trial for benign esophageal strictures.
- Capital Requirements: An incremental raise of approximately $125 million is estimated necessary to complete Phase 3 and prepare for the New Drug Application (NDA).
- Revenue Status: As a clinical-stage company, the company reported no revenue, relying on investment runway rather than commercial sales.
- Operational Efficiency: The commercial strategy targets a "buy-and-build" economic model, leveraging procedural fees (medical benefit) rather than pharmacy benefit margins to ensure physician and payer alignment.
Guidance and Future Outlook:
- Interim Data Release: Part 2 interim data for the RESOLVE trial (encompassing 60 patients at 24 weeks and 20 patients at 52 weeks) is expected in December.
- Phase 3 Timing: The company targets an End-of-Phase 2 meeting in early 2027 to finalize the registrational path for Eosinophilic Esophagitis (EoE).
- Market Projection: The addressable US patient population for EoE is projected to grow from ~470,000 currently to over 1 million by 2030, driven by a steady growth rate of 72,000 new patients annually.
- Product Launch: Anticipated launch timeline for the primary EoE indication aligns with the 2030 market maturity.
- Additional Indication: A Phase 2 trial for benign esophageal strictures (a $500M+ opportunity) is actively underway, with plans to utilize the same delivery platform.
Business Segments and Product Lines:
- Core Technology: Proprietary "Diffusphere" platform delivers fluticasone propionate via submucosal injection with zero-order kinetics, providing continuous drug release for up to 365 days from a single administration.
- Primary Indication (EoE): Targets the full esophageal length to address inflammation and fibrosis (rigidity) in Eosinophilic Esophagitis, aiming to replace or augment current therapies.
- Secondary Indication (Benign Strictures): Leveraging the same injection methodology to treat 500,000 US patients with benign strictures, potentially offering a longer-lasting alternative to steroid injections that currently last only days.
- Trial Progress: Completed recruitment for Part 1 (safety/dosing) and Part 2 (pivotal/interim) of the RESOLVE trial; Part 1 demonstrated high rates of clinical remission and fibrosis reversal.
- Procedure Integration: The treatment is designed to piggyback on standard-of-care endoscopy procedures, adding only 10 minutes or less, with no nerve-ending pain for patients.
Market and Competitive Landscape:
- Competitive Differentiation: Unlike current biologics or anti-IL-4/13 inhibitors that primarily reduce eosinophil counts without guaranteeing symptom relief, Eupraxia's therapy targets the inflammatory cascade upstream and demonstrates a strong correlation between histological improvement (EOHSS) and clinical symptom relief.
- Market Gap: Approximately 45% of the EoE market remains unaddressed by current standards, particularly patients progressing to fibrosis despite PPI therapy or those with high non-compliance rates for oral steroids.
- Physician Adoption: Recruitment rates for Eupraxia trials were double that of other EoE trials, indicating high physician interest in a solution that fits seamlessly into procedural workflows.
- Payer Alignment: The once-yearly dosing and procedural fee structure (medical benefit) aim to overcome the 70-90% non-compliance rates associated with chronic oral steroid therapy.
Risks and Challenges:
- Statistical Significance: The upcoming interim data analysis is not a registrational trial; the sample size (60 patients at 24 weeks) is not powered for statistical significance, though strong directional trends are expected.
- Endpoint Reliability: Patient-reported outcomes like the Dysphagia Symptom Questionnaire (DSQ) are described as "noisy" with high standard deviation and potential data imputation issues; the company relies on the consistency of the Strain Dysphagia Index (SDI) and histological data.
- Durability Uncertainty: While 12-month data shows sustained remission, the exact timing for re-dosing and long-term durability beyond 12 months will be determined by extended follow-up (protocol amended to 2 years).
- Regulatory Path: The company must successfully navigate the End-of-Phase 2 meeting in 2027 based on interim data to secure the path for registration.
- Funding Dependency: Despite current runway, an additional $125M raise is required to fund Phase 3 and reach NDA.
Management Commentary and Tone:
- Tone: Highly confident and optimistic, emphasizing the "remarkable" efficacy in reversing fibrosis and the unique value proposition of a once-a-year injection.
- Clinical Insight: CEO James Helliwell (a cardiothoracic anesthesiologist) leveraged clinical experience to argue that eosinophil counts are a poor surrogate for patient symptoms, positioning the company's histological focus (fibrosis reduction) as a superior differentiator.
- Strategic Clarity: Management expressed clear conviction that the product addresses a critical unmet need regarding fibrosis reversal, which current therapies fail to do effectively.
- Procedural Simplicity: Emphasized the ease of administration (5-10 seconds per injection) and safety profile (zero complications in 3,000+ injections) to reduce barriers to adoption.
Analyst Questions and Answers:
- Note: The CEO explicitly stated at the conclusion of the presentation that there would be no Q&A session due to time constraints, though he offered to connect with attendees individually afterward.
- Alternative Interaction: Investors were directed to the company website for a webinar demonstrating the injection procedure and detailed commercial strategy.
Other Key Points:
- Fibrosis Reversal: A critical differentiator is the observed reversal of esophageal rings and strictures, addressing the progressive fibrostenotic nature of EoE, not just symptom management.
- Safety Profile: The therapy demonstrated zero cases of oropharyngeal candidiasis (a common side effect of steroids/biologics) and no cortisol or adrenal suppression, even in diabetic patients.
- Safety Data: Treatment-emergent adverse events occurred in the 70% range (typical for the disease), with only one potential candidiasis case and no procedure-related complications (perforation, abscess, bleeding) across 3,000+ injections.
- Market Education: The company is actively educating the market that EoE is a progressive disease requiring fibrosis management, shifting the narrative from simple eosinophil suppression to structural tissue repair.
- Company
- EUPRAXIA PHARMACEUTICALS INC
- Keywords
- EUPRAXIA PHARMACEUTICALS INC